Switching to single-use bioreactors can have financial and performance benefits.
Yves Ghislain
Advertisement
Yves Ghislain is an expert scientist at Viral Industrial Bulk, GSK Biologicals
Articles by Yves Ghislain
Advertisement
Latest Updated Articles
Disposable Bioreactors for Viral Vaccine Production: Challenges and OpportunitiesPublished: November 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
3
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
4
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
5
